Your browser doesn't support javascript.
loading
Recent advances on smart glycoconjugate vaccines in infections and cancer.
Anderluh, Marko; Berti, Francesco; Bzducha-Wróbel, Anna; Chiodo, Fabrizio; Colombo, Cinzia; Compostella, Federica; Durlik, Katarzyna; Ferhati, Xhenti; Holmdahl, Rikard; Jovanovic, Dragana; Kaca, Wieslaw; Lay, Luigi; Marinovic-Cincovic, Milena; Marradi, Marco; Ozil, Musa; Polito, Laura; Reina, Josè Juan; Reis, Celso A; Sackstein, Robert; Silipo, Alba; Svajger, Urban; Vanek, Ondrej; Yamamoto, Fumiichiro; Richichi, Barbara; van Vliet, Sandra J.
Afiliación
  • Anderluh M; Faculty of Pharmacy, Faculty of Pharmacy, Chair of Pharmaceutical Chemistry, University of Ljubljana, Slovenia.
  • Berti F; Technical R&D, GSK Vaccines S.r.l., Siena, Italy.
  • Bzducha-Wróbel A; Department of Biotechnology and Food Microbiology, Warsaw University of Life Sciences-SGGW, Warszawa, Poland.
  • Chiodo F; Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • Colombo C; Institute of Biomolecular Chemistry (ICB), Italian National Research Council (CNR), Pozzuoli, Italy.
  • Compostella F; Department of Chemistry and CRC Materiali Polimerici (LaMPo), University of Milan, Italy.
  • Durlik K; Department of Medical Biotechnology and Translational Medicine, University of Milan, Milano, Italy.
  • Ferhati X; Department of Microbiology and Parasitology, Jan Kochanowski University, Kielce, Poland.
  • Holmdahl R; Department of Chemistry 'Ugo Schiff', University of Florence, Sesto Fiorentino, Italy.
  • Jovanovic D; Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.
  • Kaca W; Vinca Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Serbia.
  • Lay L; Department of Microbiology and Parasitology, Jan Kochanowski University, Kielce, Poland.
  • Marinovic-Cincovic M; Department of Chemistry and CRC Materiali Polimerici (LaMPo), University of Milan, Italy.
  • Marradi M; Vinca Institute of Nuclear Sciences - National Institute of thе Republic of Serbia, University of Belgrade, Serbia.
  • Ozil M; Department of Chemistry 'Ugo Schiff', University of Florence, Sesto Fiorentino, Italy.
  • Polito L; Faculty of Arts and Sciences, Department of Chemistry, Recep Tayyip Erdogan University, Rize, Turkey.
  • Reina JJ; National Research Council, CNR-SCITEC, Milan, Italy.
  • Reis CA; Departamento de Química Orgánica, Universidad de Málaga-IBIMA, Spain.
  • Sackstein R; Andalusian Centre for Nanomedicine and Biotechnology-BIONAND, Parque Tecnológico de Andalucía, Málaga, Spain.
  • Silipo A; I3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal.
  • Svajger U; IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Portugal.
  • Vanek O; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal.
  • Yamamoto F; Department of Translational Medicine, Translational Glycobiology Institute, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
  • Richichi B; Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario Monte Sant'Angelo, Napoli, Italy.
  • van Vliet SJ; Blood Transfusion Center of Slovenia, Ljubljana, Slovenia.
FEBS J ; 289(14): 4251-4303, 2022 07.
Article en En | MEDLINE | ID: mdl-33934527
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen-specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T-cell immunity in the fight against cancer. The recent SARS-CoV-2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan-coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as "tumor-associated carbohydrate antigens". Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T-cell-independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 / Neoplasias Límite: Humans Idioma: En Revista: FEBS J Asunto de la revista: BIOQUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 / Neoplasias Límite: Humans Idioma: En Revista: FEBS J Asunto de la revista: BIOQUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Eslovenia Pais de publicación: Reino Unido